22:23 , Apr 22, 2019 |  BC Extra  |  Financial News

Poseida postpones IPO in favor of $142M series C

Poseida raised a $142 million series C round Monday that includes a $75 million contribution from Novartis AG (NYSE:NVS; SIX:NOVN). CEO Eric Ostertag told BioCentury that Poseida Therapeutics Inc. (San Diego, Calif.) has withdrawn the...
16:51 , Apr 22, 2019 |  BioCentury  |  Finance

Poseida's sea change

Rather than execute the IPO it proposed in January, Poseida has instead raised a $142 million series C round that includes a $75 million contribution from Novartis. CEO Eric Ostertag told BioCentury that Poseida has...
10:32 , Apr 22, 2019 |  BC Extra  |  Company News

Lilly pays $35M up front to partner with Avidity on oligo conjugates

Lilly partnered with Avidity to develop antibody-oligonucleotide conjugates to treat immune diseases, with the biotech receiving $20 million up front and a $15 million investment. Avidity Biosciences LLC (La Jolla, Calif.) is eligible to receive...
10:30 , Apr 1, 2019 |  BC Extra  |  Financial News

SpringWorks raises $125M series B round

A year and a half after raising its initial round of funding to develop programs spun out of Pfizer, SpringWorks has raised $125 million in a series B round. The company now has funding to...
23:43 , Mar 27, 2019 |  BC Extra  |  Financial News

Gene therapy company Prevail raises $50M series B

Prevail raised $50 million in a series B round to advance its pipeline of gene therapies for neurodegenerative diseases. Existing investors participating in the round included OrbiMed Advisors, Pontifax, RA Capital Management, EcoR1 Capital, Omega...
22:56 , Jan 25, 2019 |  BioCentury  |  Finance

Venrock spreads HAE bets

Venrock is broadening its portfolio of oral hereditary angioedema therapy investments by leading a $23 million series B round that will allow Attune Pharmaceuticals to move its lead plasma kallikrein (KLKB1) inhibitor into Phase II...
00:37 , Jan 25, 2019 |  BC Week In Review  |  Financial News

Attune raises $23M, reports safety data for angioedema candidate

Rare diseases company Attune Pharmaceuticals (New York, N.Y.) raised $23 million on Jan. 23 in a series B round on the back of reporting Phase I data for its lead oral plasma kallikrein (KLKB1) inhibitor,...
19:35 , Jan 24, 2019 |  BC Innovations  |  Emerging Company Profile

Cabaletta’s CAAR Ts for autoimmunity

Cabaletta Bio Inc.’s CAAR T therapy is geared to treat B cell-mediated autoimmunity without wiping out all B cells. The company is betting an antigen-specific approach will yield efficacy without CARs’ safety drawbacks. Cabaletta spun...
14:54 , Jan 23, 2019 |  BC Extra  |  Financial News

Attune raises $23M, reports safety data for angioedema candidate

Rare diseases company Attune Pharmaceuticals (New York, N.Y.) raised $23 million in a series B round Wednesday on the back of reporting Phase I data for its lead oral plasma kallikrein (KLKB1) inhibitor, ATN-249, to...
19:06 , Jan 4, 2019 |  BC Week In Review  |  Financial News

Venture roundup: Cabaletta, Thousand Oaks, Sojournix

Autoimmune company Cabaletta Bio Inc. (Radnor, Pa.), CMC services play Thousand Oaks Biopharmaceuticals Inc. (Haimen, China) and women's health company Sojournix Inc. (Waltham, Mass.) each announced venture rounds of at least $44 million on Jan....